Interim Results From ADmirable, a Phase 3b Open-Label Study Assessing Lebrikizumab in Patients With Skin of Color and Moderate-to-Severe Atopic Dermatitis

BACKGROUND
- Lebrikizumab is a novel monoclonal antibody that binds with high affinity and slow off-rate to IL-13, thereby blocking the downstream effects of IL-13 with high potency.
- The efficacy and safety of lebrikizumab to treat moderate-to-severe AD have been established in Phase 3 studies, including subgroup analyses by race and ethnicity.
- There is a paucity of data to guide the treatment of moderate-to-severe AD in populations traditionally under-represented in clinical trials, including patients with skin of color.
- ADmirable (NCT0372419) is the first Phase 3, open-label, 24-week study to evaluate the efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe AD skin of color.

OBJECTIVE
- To present the baseline demographics, clinical characteristics, and 16-week efficacy results from an interim analysis of ADmirable.

METHODS
Study Design
- Outcomes
  - Week 16 Outcomes
    - Proportion of patients achieving:
      - EASI 75/90
      - IGA (0,1) with ≥2 point improvement from baseline
      - Pruritus NRS 24- and 23-point improvement from baseline
  - Mean percent change in:
    - EASI
    - Pruritus NRS
  - Changes in post-inflammatory hyperpigmentation (PIH) lesions as measured by PDCA-Derm™

- Results
  - Baseline Demographics
  - Disease Characteristics
  - Statistical Analyses

RESULTS
- Baseline Demographics
- Disease Characteristics
- Statistical Analyses

CONCLUSIONS
- This is the first clinical trial of lebrikizumab for patients with moderate-to-severe AD:
  - With skin of color
  - Using objective and subjective tools and scales to evaluate signs and symptoms that matter to patients
- Lebrikizumab improved AD signs and symptoms in patients with skin of color and moderate-to-severe AD after 16 weeks of treatment, with:
  - EASI 75 achieved in 68% of patients
  - IGA (0,1) with 22-point improvement achieved in 39% of patients
- Pruritus NRS 24-point improvement achieved in 56% of patients
- No serious adverse events observed
- The innovative objective measure PDCA-Derm™ identified improvement in post-inflammatory hyperpigmentation lesions in 1272 patients and improvement in normal skin tone in 621 patients at Week 16

EASI Responses From Week 0 to Week 16 (N=50)

PDCA-Derm™: A Scale Used to Compare Post-Inflammatory Lesions to Normal Skin

Use of Concomitant Topical and Systemic Therapy

Copyright ©2024 Eli Lilly and Company. All rights reserved.